COMP <GO>
RXRX vs JNJ // REVENUE GROWTH (YOY)
Recursion Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RXRX 2
— JNJ 11
▲ REVENUE GROWTH (YOY) LEADER: RXRX
LAST: $4.03 (-4.95%) • MKT CAP: $2.53B
revenue-growth
26.90%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXRX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXRX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.00% | 67.90% | -62.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.95% | 2.97% | -17.92 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 26.90% | 6.00% | +20.90 | RXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.59 | 5.59 | -4.00 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | RXRX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.6 | 60.4 | -7.76 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.08 | -0.08 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 23.0x | +9.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.53B | $662.49B | -$659.96B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXRX REV | JNJ REV | RXRX GROSS % | JNJ GROSS % | RXRX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $74.7M | $94.19B | 5.0% | 67.9% | -$378.3M | $19.70B |
| FY 2024 | $58.8M | $88.82B | 23.1% | 69.1% | -$372.9M | $19.84B |
| FY 2023 | $44.6M | $85.16B | 44.0% | 44.0% | -$289.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXRX // BETA 1.00
JNJ // BETA 1.08